US Court denies review of Ranbaxy's plea on patent
The battle for a slice of Pfizer's $12-billion cholesterol drug Lipitor was expected to be a fight to the finish. And Lipitor's patent-challenger, Ranbaxy is not flinching despite reports that a US
The battle for a slice of Pfizer's $12-billion cholesterol drug Lipitor was expected to be a fight to the finish. And Lipitor's patent-challenger, Ranbaxy is not flinching despite reports that a US